Mar 1, 2024 · C5 complement inhibition is an effective therapeutic approach in the treatment of NMOSD. In this systematic review and meta-analysis, we aimed to determine the role of C5 inhibitors in the treatment of patients with seropositive …

Clinical studies supported the approval of eculizumab, an inhibitor of C5 cleavage, in AQP4-IgG seropositive NMOSD. This review covers in vitro, animal models and human evidence for complement-dependent and complement-independent …

Mar 25, 2024 · Ultomiris (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). 1

C5 complement inhibition is an effective therapeutic approach in the treatment of NMOSD. In this systematic review and meta-analysis, we aimed to determine the role of C5 inhibitors in the treatment of patients with seropositive anti-aquaporin-4 antibody (AQP4+IgG) NMOSD.

Compelling evidence supports a pathogenic role for complement activation following AQP4-IgG binding to AQP4. Clinical studies supported the approval of eculizumab, an inhibitor of C5 cleavage, in AQP4-IgG seropositive NMOSD.

New and emerging drugs that inhibit cleavage of the C5 complement protein have delivered notably improved outcomes in phase 3 clinical trials. One of these, eculizumab, is now approved by the US Food and Drug Administration (FDA) for treatment of NMOSD.

Apr 4, 2019 · Using phage display, we sought to screen single-chain variable fragments (scFvs) against complement C5 to treat neuromyelitis optica spectrum disorder (NMOSD). After 5 rounds of phage display, we isolated individual clones and identified phage clones specifically binding to C5 using ELISA.

Nov 30, 2023 · C5 complement inhibition is an effective therapeutic approach in the treatment of NMOSD. In this systematic review and meta-analysis, we aimed to determine the role of C5 inhibitors in the treatment of patients with seropositive …

4 days ago · It inhibits the cleavage of complement protein C5 into pro-inflammatory components C5a and C5b. 39 The PREVENT study investigated the efficacy and safety of eculizumab in NMOSD. 40 Between 2014 and 2017, 143 adult AQP4-IgG-seropositive NMOSD patients were randomized in 2:1 to receive either eculizumab or placebo. The study was terminated early ...

Oct 11, 2023 · A recent analysis of the PREVENT and CHAMPION-NMOSD found no significant differences in safety outcomes for patients with AQP4+ NMOSD who were treated with rituximab prior to starting C5 complement inhibitors in specific timeframes.